The effect of newer serotonin-noradrenalin antidepressants on cytokine production: A review of the current literature

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 2, 2010, Pages 417-422

  De Berardis, Domenico ^a,b,c   Conti, C M V ^a   Serroni, N ^b   Moschetta, F S ^b   Olivieri, L ^b   Carano, A ^c   Salerno, R M ^a   Cavuto, M ^d   Farina, B ^a   Alessandrini, M ^a   Janiri, L ^e   Pozzi, G ^e   Di Giannantonio, M ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b G Mazzini Hospital   (Italy)

^c Department of Mental Health   (Italy)

^d IASM   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antidepressant; Cytokines; Depression; Duloxetine; Mirtazapine; Noradrenaline; Serotonin; Venlafaxine

Indexed keywords

DULOXETINE; FLUOXETINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 6; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID; PAROXETINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VENLAFAXINE;

ALLERGIC ENCEPHALOMYELITIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; HUMAN; MAJOR DEPRESSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

EID: 77955353241     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300204     Document Type: Review

References (31)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-76.
2. Paykel ES. Depression: major problem for public health. Epidemiol Psichiatr Soc 2006; 15:4-10.
3. Glassman AH. Depression and cardiovascular comorbidity. Dialogues Clin Neurosci 2007; 9:9-17.
4. De Berardis D, Campanella D, Gambi F, et al. The role of C-reactive protein in mood disorders. Int J Immunopathol Pharmacol 2006; 19:721-5. (Pubitemid 46145036)
5. De Berardis D, Conti CM, Campanella D, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol 2008; 21:319-24. (Pubitemid 351988393)
6. Kempuraj D, Konstantinidou A, Boscolo P, et al. Cytokines and the brain. Int J Immunopathol Pharmacol 2004; 17:229-32.
7. Di Giannantonio M, Frydas S, Kempuraj D, et al. Cytokines in stress. Int J Immunopathol Pharmacol 2005; 18:1-5.
8. De Berardis D, Serroni N, Campanella D, et al. Alexithymia and its relationships with C-reactive protein and serum lipid levels among drug naïve adult outpatients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1982-6.
9. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003; 54:283-94.
10. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002; 5:401-12.
11. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 1999; 65:1773-86. (Pubitemid 29481260)
12. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21:199-206. (Pubitemid 32221058)
13. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007; 12:988-1000. (Pubitemid 350006207)
14. Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, Scharpe S, Budziszewska B, Maes M. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 2004; 4: 185-92. (Pubitemid 38296348)
15. Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006; 6:1298-304.
16. Vollmar P, Haghikia A, Dermietzel R, Faustmann PM. Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. Int J Neuropsychopharmacol 2008; 11:111-7.
17. Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol 2008; 16:1-12.
18. Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, Lindsay Devane C. Proinflammatory biomakers in depression: Treatment with venlafaxine. World J Biol Psychiatry 2008; 31:1-11.
19. De Berardis D, Serroni N, Carano A, et al. The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat 2008; 4:929-35.
20. Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia: new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 2006; 19:5-10.
21. Gambi F, De Berardis D, Sepede G, et al. Effect of mirtazapine on thyroid hormones in adult patients with major depression. Int J Immunopathol Pharmacol 2005; 18:737-44.
22. Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 2005; 19:483-7.
23. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002; 35:220-5. (Pubitemid 36061311)
24. Kast RE. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry 2003; 25:495-6.
25. Kubera M, Roman A, Basta-Kaim A, et al. Effect of acute and repeated treatment with mirtazapine on the immunity of noradrenaline transporter knockout C57BL/6J mice. Pharmacol Biochem Behav 2006; 85:813-9.
26. Gosain A, Muthu K, Gamelli RL, Di Pietro LA. Norepinephrine suppresses wound macrophage phagocytic efficiency through alpha- and beta-adrenoreceptor dependent pathways. Surgery 2007; 142:170-9. (Pubitemid 47198679)
27. Zhu J, Wei X, Feng X, Song J, Hu Y, Xu J. Repeated administration of mirtazapine inhibits development of hyperalgesia/allodynia and activation of NF-kappaB in a rat model of neuropathic pain. Neurosci Lett 2008; 433:33-7.
28. Di Gioacchino M, Perrone A, Petrarca C, et al. Early cytokine modulation after the rapid induction phase of sublingual immunotherapy with mite monomeric allergoids. Int J Immunopathol Pharmacol 2008; 21:969-76.
29. Spedding M, Gressens P. Neurotrophins and cytokines in neuronal plasticity. Novartis Found Symp 2008; 289:222-33.
30. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 2009; 34:4-20.
31. Khairova RA, Machado-Vieira R, Du J, Manji HK. Potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009; 12:561-78.